Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idarubicin-ZHER2 affibody conjugate
- Development stage
- Preclinical
- Lead developer
- Ahvaz Jundishapur University of Medical Sciences
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
**Idarubicin-ZHER2 affibody conjugate** is an experimental HER2-targeted peptide-drug conjugate in which the anthracycline cytotoxic payload idarubicin is covalently linked to a dimeric ZHER2 affibody targeting ligand. The affibody binds human epidermal growth factor receptor 2 on HER2-overexpressing tumor cells to preferentially deliver idarubicin, whose intracellular anthracycline activity includes DNA intercalation and inhibition of DNA topoisomerase II. Published preclinical studies reported preferential cytotoxicity in HER2-overexpressing ovarian cancer and head and neck squamous cell carcinoma cell models; an additional mouse study evaluated its immunogenicity following intravenous administration. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8085286/))
- Other names
- ZHER2-idarubicin conjugateZHER-2-idarubicin conjugateZHER 2-idarubicin conjugateidarubicin-ZHER2 affibody conjugateidarubicin-ZHER-2 affibody conjugateidarubicin-ZHER 2 affibody conjugateidarubicin-ZHER2 conjugateidarubicin-ZHER-2 conjugateidarubicin-ZHER 2 conjugate
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on idarubicin-ZHER2 affibody conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idarubicin-ZHER2 affibody conjugate.